GlobeNewswire

Kane Biotech Announces New Private Placement Offering
07/05/2026
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today [...]
Legacy Opens Pasadena Southmore Clinic to Address Critical Health Care Needs
07/05/2026
New two-story clinic brings integrated, affordable care under one roof for Pasadena families HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pasadena gains a new health care lifeline with the opening of the Legacy Pasadena [...]
Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants
07/05/2026
CARLSBAD, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery [...]
Entrada Therapeutics Reports First Quarter 2026 Financial Results
07/05/2026
-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201 Cohort 1 [...]
TerrAscend Reports First Quarter 2026 Financial Results
07/05/2026
Net Revenue of $65.5 million and Gross Profit Margin of 52.8% for Q1 2026 Q1 2026 Net Cash Provided from Continuing Operations of $8.7 million, representing 13.3% Operating Cash Flow Yield 1 Q1 2026 Free Cash Flow 1 of [...]
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
07/05/2026
1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS [...]
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
07/05/2026
NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
07/05/2026
Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 [...]
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07/05/2026
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in [...]
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
07/05/2026
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal [...]
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
07/05/2026
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relapsed EGFR ex20ins [...]
Ligand Reports First Quarter 2026 Financial Results
07/05/2026
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA [...]
Axsome Therapeutics Recognizes Mental Health Month
07/05/2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support [...]
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
07/05/2026
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in [...]
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
07/05/2026
CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel [...]
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
07/05/2026
Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); [...]
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
07/05/2026
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP [...]
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
07/05/2026
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial [...]
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
07/05/2026
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum